Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales

The firm credited "strong demand" for its next-gen-sequencing tools and restored growth in its array business, particularly for whole-genome genotyping chips for the spike in sales.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.